Oncotelic Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2013 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Oncotelic Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2013 to Q1 2024.
  • Oncotelic Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $0.000.
  • Oncotelic Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $0.000, a 100% decline from 2022.
  • Oncotelic Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $900K, unchanged from 2021.
  • Oncotelic Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $900K.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $0 $0 Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q1 2023 $600K $0 -$300K -100% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $900K $275K Oct 1, 2022 Dec 31, 2022 10-K 2024-04-12
Q3 2022 $300K $0 0% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-18
Q2 2022 $25K Apr 1, 2022 Jun 30, 2022 10-Q 2022-08-22
Q1 2022 $300K +$300K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-22
Q3 2021 $300K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-18
Q1 2021 $0 -$2.1M -100% Jan 1, 2021 Mar 31, 2021 10-Q 2021-11-22
Q1 2020 $2.1M +$1.76M +516% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-24
Q1 2020 $2.1M +$1.76M +516% Feb 1, 2020 Feb 29, 2020 10-Q 2021-11-22
Q1 2019 $341K +$157K +85.3% Apr 1, 2019 Apr 30, 2019 10-K 2021-04-15
Q1 2019 $212K +$28K +15.2% Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-15
Q1 2018 $184K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q3 2013 $200K Jul 1, 2013 Sep 30, 2013 10-Q 2013-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.